Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.K. Newco Raises £6 Mil. To Discover Ubiquitin-Targeting Cancer Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Cancer-focused Mission Therapeutics attracts £6 million Series A, including corporate VC.

You may also be interested in...



Servier Research Deals Suggest Business-As-Usual For Scandal-Ridden Firm

Still reeling from the Mediator scandal, Servier's two latest cancer research deals suggest the French company is trying to move forward.

Servier Research Deals Suggest Business-As-Usual For Scandal-Ridden Firm

Still reeling from the Mediator scandal, Servier's two latest cancer research deals suggest the French company is trying to move forward.

Belgium's Amakem Raises €18 million In Europe's Largest Series A So Far In 2011

Belgian start-up raises record-breaking €18 million A round to take rho kinase inhibitor glaucoma candidate to clinical proof-of-concept.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS072693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel